Anti-hyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial.

Okra (Abelmoschus esculentus) has traditionally been used in diabetes treatment. This study investigated the effect of Okra whole fruit on blood glucose level of patients with diabetes mellitus type 2 with concomitant use of oral hypoglycemic agents. In this double-blind randomized clinical trial, 120 diabetic patients were assigned to okra group (n = 60) and control group (n = 60). The okra group received 1,000 mg of A.esculentus whole fruit capsules orally, every 6 hr for 8 weeks. The control group received placebo capsule in the same manner. The levels of FBS (fasting blood sugar), BS (blood sugar), and Hemoglobin A1C (HgA1c) were measured at baseline and after intervention in both groups. The levels of FBS, BS, and HgA1c were significantly decreased in okra group within the intervention compared to control group (p < .05). Moreover, the numbers to treat (NNT) for FBS, BS, and HgA1C were seven, eight, and seven, respectively. Okra whole fruit supplementation has a promising anti-hyperglycemic effect in patients with diabetes mellitus type 2 who received oral agents. Diabetic patients could benefit from adjuvant therapy of okra with other medication.